DW Healthcare Partners

What DW Healthcare Partners does

DW Healthcare Partners (DWHP) is a Toronto-based, healthcare-exclusive private equity firm founded in 2002 that invests in mid-stage North American healthcare companies through two complementary fund strategies. The Main Fund targets companies with $10+ million USD EBITDA, deploying $50-70 million in equity and typically seeking majority ownership, while the Founders Fund (DW Healthcare Partners Small Cap, L.P., closed March 2023 at $210 million) targets lower middle market healthcare companies with $3-6 million USD EBITDA, deploying $15-20 million in equity. The firm operates across two offices (Toronto, Ontario and Park City, Utah) under the legal entity DW Management Services, LLC, and is led by Co-Founders Andrew Carragher (Managing Partner, Harvard MBA) and Jay Benear (Managing Director and CCO, MD credential), alongside Managing Directors Doug Schillinger, Eric Moore, Gabe Becher, and Aly Champsi.

The firm has completed 46 platform investments and 81 add-on acquisitions since inception, building a portfolio spanning medical devices (LKC Technologies, CEFALY, DermLite, Spectrum Solutions), animal health and pharmaceuticals (Parnell, Vets Plus, Bio Agri Mix, Med-Pharmex), healthcare services (360 Behavioral Health, Care XM, SoClean, WillowWood), medical education (Med Learning Group), diagnostics, specialty distribution, and beauty health (HydraFacial). DWHP does not sell technology products; its core competency is healthcare industry expertise, proprietary deal sourcing across a database of more than 66,000 healthcare companies, and operational value creation through board participation and add-on acquisition support.

Revenue is generated through the standard private equity model: recurring management fees on committed capital under management (currently $2.7 billion AUM across six funds) plus performance-based carried interest from successful exits. Notable exits include the HydraFacial SPAC merger (The Beauty Health Company, Nasdaq: SKIN, May 2021) co-led with Linden Capital Partners, the sale of Med-Pharmex to Dechra Pharmaceuticals (August 2022), the sale of WillowWood Global to Blue Sea Capital (December 2021), the sale of DermLite to FotoFinder Systems (March 2024), and the sale of LKC Technologies to AMETEK (February 2026). The firm's limited partners include corporate pension plans, insurance companies, foundations, fund of fund managers, high net worth family trusts, and endowments.

Name

DW Healthcare Partners

Legal name

DW Management Services, LLC

Website

http://dwhp.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

DW Healthcare Partners is a Toronto-based private equity firm founded in 2002 that invests exclusively in mid-stage North American healthcare companies through a Main Fund and a Founders Fund, deploying $15-70 million per deal across 46 platforms and 81 add-ons with $2.7 billion in AUM.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Healthcare private equity
• Growth capital investments
• Buyout transactions
• Portfolio management
• Healthcare investments

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Management Fees: Private equity firms typically charge management fees on committed capital under management. DWHP manages six funds with over $2.7 billion in assets under management.
2. Carried Interest: Performance-based carried interest from successful fund investments and exits. The firm has completed 46 platform investments and 81 add-ons since inception, with successful exits including HydraFacial (SPAC merger), LKC Technologies (sold to AMETEK), DermLite (sold to FotoFinder), Med-Pharmex (sold to Dechra), and others.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

DW Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. The firm invests in mid-stage healthcare companies through control and minority buyout transactions, shareholder liquidity events, management buyouts, and growth capital for add-on acquisitions across North America. Capital is deployed through two primary funds (Main Fund and Founders Fund) targeting companies with $3M+ in EBITDA.

Product overview

DW Healthcare Partners is a healthcare-focused private equity firm founded in 2002, not a product/technology company. The firm manages six funds with over $2.7 billion in assets under management and has completed 46 platform investments plus 81 add-ons. The firm provides capital, strategic guidance, and acquisition support to help mid-stage healthcare companies grow and scale. The company does not offer products or services in the traditional SaaS/product sense; rather, it operates as a private equity investment firm with portfolio companies including BAM, CareXM, Cefaly, Med Learning Group, Parnell, Vets Plus, 360 Behavioral Health, Aequor, Champion, HydraFacial, SoClean, Spectrum Solution, and TubeWriter.

Differentiator

Problem solved

Functional benefit

Brands

• Founders Fund: DW Healthcare Partners Small Cap, L.P. - a fund focused on lower middle market healthcare investments targeting companies with $3 to 6 million USD EBITDA.

Products and services

• DWHP Main Fund

Quantifiable outcome

• 46 platform investments completed since inception
• +3 more outcomes

Named customers14 records

Segments3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• The Vistria Group: Chicago-based middle-market PE firm with a healthcare practice spanning services, behavioral health, and medical products. Overlaps with DWHP in behavioral health (360 Behavioral Health) and healthcare services.
• Ampersand Capital Partners: Healthcare and life sciences-focused PE firm investing in pharma services, diagnostics, and specialty healthcare. Closely comparable by healthcare-only mandate and mid-market deal size.
• Frazier Healthcare Partners: Seattle-based healthcare-only PE firm investing across services, pharma, and medtech at the growth and buyout stages. Comparable by healthcare focus, deal size range, and partnership-style model.
• Arsenal Capital Partners: Healthcare and specialty industrials PE firm investing in lower-mid-market companies. Comparable by sector focus (healthcare services, pharma services) and equity check size.
• Avista Capital Partners: Healthcare-focused middle-market PE firm investing in pharma, medtech, and healthcare services. Directly comparable in mandate, check size, and operating partner involvement.
• Linden Capital Partners: Healthcare-focused middle-market private equity firm based in Chicago. Linden co-invested with DWHP in HydraFacial and shares a similar thesis of healthcare-only control buyouts in the mid-market.

Broad incumbents

• New Mountain Capital: Large healthcare-services and information services PE firm. Overlaps with DWHP on healthcare services and devices but at significantly higher AUM and broader sector coverage.
• GTCR: Chicago-based diversified PE firm with a long-running Leaders Strategy healthcare franchise. Comparable mid-market healthcare deal flow but with broader sector breadth.
• Welsh, Carson, Anderson & Stowe: Larger healthcare-services-and-technology-focused PE firm with broader tech crossover mandates. Comparable in healthcare specialization but operates at meaningfully larger AUM scale.

Emerging players

• HealthCare Royalty Partners: Healthcare-specialist investment firm focused on healthcare-related royalties and structured deals. Adjacent comparable given healthcare-only mandate, though structured differently than control buyouts.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Investments23 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DW Healthcare Partners